Target Audience of “Alzheimers Disease (AD) Diagnostics and Therapeutics Market” Report 2018: Manufacturer / Potential Investors, Traders, Distributors, Wholesalers, Retailers, Importers and Exporters, Association and government bodies.
Alzheimers Disease (AD) Diagnostics and Therapeutics Market Report provides key statistics on the market status of the Alzheimers Disease (AD) Diagnostics and Therapeutics Manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the Alzheimers Disease (AD) Diagnostics and Therapeutics Industry.
The Global Alzheimerâs diagnostics and therapeutics market was valued at approximately USD 7,100 million for 2017 and is expected to register a CAGR of approximately 6.7% during the forecast period (2018-2023). North America holds the largest share among the geographical regions.
Investment in Biomarkers for Drug Development
Alzheimerâs disease (AD) is one of the most prevalent dementia in the world. According to the Alzheimerâs disease facts and figures, it is estimated that in every 33 seconds, a new case of AD occurs, a very high prevalence of almost 35 million patients around the world. Consequently, the development of clinical diagnostics and therapeutics for AD and other neurodegenerative conditions is becoming very important. In about 10% to 15% of cases, clinical diagnosis of AD is inaccurate. To overcome this hurdle, certain biomarkers are used, which improve the accuracy of the diagnosis. Biomarkers are neurochemical indicators that are used to access the risk or prevalence of a disease. Biomarkers also find application in drug development for AD. Several biomarkers are used for the detection of various stages of Alzheimerâs disease. Examples include beta-amyloid and tau levels in the cerebrospinal fluid and brain changes that are detectable by imaging. Recently, researchers at the Sanford Burnham Prebys Medical Discovery Institute (SBP) identified a new biomarker, which is a peptide (DAG) that may lead to early detection of AD. The peptide identifies a protein that increases in the brain blood vessels of mice and human Alzheimer patients. Thus, investments in the development of biomarkers for drug development and early detection of AD are acting as the major driver and fuelling the growth of the Alzheimers disease diagnostics & therapeutics market globally.
Other factors that help in the growth of the market are increasing pipeline drug development, increasing incidence and prevalence of Alzheimers disease, increasing sophisticated diagnostics for early detection and precise drug development, and emerging novel diagnostic techniques.
Early Diagnosis of the Indication is challenging
Alzheimerâs disease (AD) is becoming a major public health threat, due to the increasing number of the affected individuals. According to the Translational Research & Clinical Intervention, there are 5.3 million Americans and 35 million people worldwide that are suffering from Alzheimer disease. As Alzheimer disease is spreading in the world, new therapies are urgently needed for the diagnosis and treatment of the disease. Early diagnosis of AD is challenging, and the early symptoms of the AD are commonly overlooked, because the symptoms are mild and the anatomical changes in the brain and central nervous symptoms are not necessarily visible through medical imaging. This limitation has serious implications, as late-stage diagnosis leaves the patients with only symptomatic relief options through medications, thereby limiting the overall benefit the patient could have received through early medication and diagnosis. Consequently, the limitations in early-stage diagnosis of AD is constraining the growth of the AD diagnostics and therapeutics market globally.
Other factors restraining the market are decrease in the market due to failures of late-stage drugs, lack of surrogate markers for drug discovery and drug development, and insufficient research funding and lengthy uncertain processes.
The United States is the global leader in AD Intervention and Management
According to the Alzheimerâs Association, more than 5 million Americans are living with AD, as of 2017. The United States is considered as the global leader in Alzheimerâs disease intervention and management. The United States has a large pool of biopharmaceutical companies, which cumulatively have a total of 85 drugs in various stages in the pipeline for combating Alzheimerâs disease. The United States holds a major share of around 83% of the total revenue in North America.
Get PDF Sample of Alzheimers Disease (AD) Diagnostics and Therapeutics Market Report @ https://www.360marketupdates.com/enquiry/request-sample/12886627
Major companies covered in this Report:
Reasons to Purchase the Report
Purchase Alzheimers Disease (AD) Diagnostics and Therapeutics Market Report at @ https://www.360marketupdates.com/purchase/12886627
Finally, the feasibility of new investment projects is assessed, and overall research conclusions are offered. In this KEYWORD Market analysis, traders and distributors analysis is given along with contact details. For material and suppliers also, contact details are given. New investment feasibility analysis is included in the report.